Trial tests Immune-Boosting drug combo for Tough-to-Treat cancer
NCT ID NCT03075527
Summary
This study tested whether a combination of two immunotherapy drugs, durvalumab and tremelimumab, could help control advanced malignant pleural mesothelioma. It was for people whose cancer had progressed after standard chemotherapy. The goal was to see if boosting the body's immune system could shrink tumors and extend life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MESOTHELIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.